icon-folder.gif   Conference Reports for NATAP  
 
  Paris Special EASL Meeting
Pais, France
September 23-24, 2016
Back grey_arrow_rt.gif
 
 
 
GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Patients With Genotype 1a Chronic Hepatitis C Virus Infection Without Cirrhosis
 
 
  Reported by Jules Levin
 
EASL Special Conference, New Perspectives in Hepatitis C Virus Infection- Roadmap for the Cure, 23-24 September 2016, in Paris, France
 
Fred Poordad1, Shahriar Sedghi2, Paul J Pockros3, Natarajan Ravendhran4, Robert Reindollar5, Michael R Lucey6, Michael Epstein7, Leslie Bank8, David Bernstein9, Roger Trinh10, Preethi Krishnan10, Tami Pilot-Matias10, Akshanth R Polepally10, Rajvineeth Kumar Pothacamury10, Kristina Unnebrink12, Marisol Martinez10, David R Nelson11 1Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, United States; 2Associate Professor of Medicine and Surgery, Mercer University School of Medicine, Macon, Georgia, United States; 3Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, California, United States; 4Digestive Disease Associates, Baltimore, Maryland, United States; 5Piedmont Healthcare/Carolinas Center for Liver Disease, Statesville, North Carolina, United States; 6Division of Gastroenterology/Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States; 7Anne Arundel Medical Center, Digestive Disorders Associates, Annapolis, Maryland, United States; 8Principal Investigator, Regional Clinical Research Inc., Endwell, New York, United States; 9Hofstra Northwell School of Medicine, Manhasset, New York, United States; 10AbbVie Inc., North Chicago, Illinois, United States; 11Department of Medicine, University of Florida, Gainesville, Florida, United States; 12AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany

IAC1

IAC22

KeyEl

IAC4

IAC5

IAC6

IAC6

IAC7

IAC8

IAC9